Discounted Cash Flow
Strata Critical Medical, Inc.
—
—
Average annual growth rates
| Metric | 10-Year | 5-Year | 3-Year |
|---|---|---|---|
| Sales | — | — | — |
| Free Cash Flow | — | — | — |
| Average (FCF & NI) | — | — | — |
| Net Income | — | — | — |
| Dividends | — | — | — |
Endpoint CAGR (better for long term trend)
| Metric | 10-Year | 5-Year | 3-Year |
|---|---|---|---|
| Sales | — | — | — |
| Free Cash Flow | — | — | — |
| Average (FCF & NI) | — | — | — |
| Net Income | — | — | — |
Projected growth rate
—
—
%
%
Historical inputs (10 fiscal years)
| YEAR | Sales | Net Income | Free Cash Flow | Net Margin | EPS (diluted) |
|---|---|---|---|---|---|
| 2019 | $31.2m | $-10.8m | $-10.3m | -34.7% | $-0.43 |
| 2020 | $23.4m (-24.9%) | $127.7k (101.2%) | $-794.5k (92.3%) | 0.5% (101.6%) | $-0.40 (7.0%) |
| 2021 | $50.5m (115.6%) | $-40.1m (-31459.7%) | $-15.6m (-1865.5%) | -79.3% (-14644.7%) | $-0.93 (-132.5%) |
| 2022 | $146.1m (189.2%) | $-27.3m (31.9%) | $-37.1m (-137.8%) | -18.7% (76.5%) | $-0.38 (59.1%) |
| 2023 | $225.2m (54.1%) | $-56.1m (-105.7%) | $-32.3m (12.9%) | -24.9% (-33.5%) | $-0.76 (-100.0%) |
| 2024 | $248.7m (10.4%) | $-16.2m (71.2%) | $-2.9m (91.1%) | -6.5% (73.9%) | $-0.21 (72.4%) |
| 2025 | $197.1m (-20.7%) | $-20.1m (-24.2%) | $-49.0m (-1594.6%) | -10.2% (-56.6%) | $-0.24 (-14.3%) |
Base FCF: — (latest fiscal year)
Discount rate: % —
Terminal growth: —
Projection period: — years
Alt A decline yrs:
Alt B total yrs:
Projected cash flows
| Year | Projected cash flow | Discount Factor | Present Value |
|---|
PV of projected FCF: —
Terminal FCF: —
Terminal value: —
PV of terminal value: —
Enterprise value (DCF): —
Current price: —
—Alternative DCF Models
| Model | Fair Value | Upside | PV(FCFs) | PV(Terminal) | Total Years |
|---|---|---|---|---|---|
| Standard (10yr→TV) | — | — | — | — | 10 + TV |
| Alt A (Gradual Decline) | — | — | — | — | — |
| Alt B (30yr Hard Stop) | — | — | — | N/A | — |
This is a simplified DCF model for illustration. It uses reported free cash flow, a single growth assumption, fixed WACC, and a Gordon Growth terminal value. It is not investment advice.